{"name":"Mathew S. Maurer","slug":"mathew-s-maurer","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Erythropoietin alpha","genericName":"Erythropoietin alpha","slug":"erythropoietin-alpha","indication":"Anemia associated with chronic kidney disease","status":"phase_2"}]}],"pipeline":[{"name":"Erythropoietin alpha","genericName":"Erythropoietin alpha","slug":"erythropoietin-alpha","phase":"phase_2","mechanism":"Erythropoietin alpha stimulates erythropoiesis by binding to the erythropoietin receptor.","indications":["Anemia associated with chronic kidney disease","Anemia associated with chemotherapy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE52cnY2MU50UExNV3Z1NnVEcHBNTHBtRTRQaHlXRjYycTBCRVhvaGFFMkxOV1gyZ281cWtndE9EZm5RQll0SkJQdUpPcnhjT2NFdFUwUjdrMXRKTmhTaHVGS0JZd0o5R0hILV9FYzQ3aXJQRHpZdHc4UQ?oc=5","date":"2025-11-10","type":"trial","source":"American Heart Association Journals","summary":"Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial - American Heart Associ","headline":"Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNN0FTYVlZRTVpS1RUV2ZXVUJmVEVBTzl5TzR5eW9TaXVkVkEzMzIycUFJNjl1WlduWFVNUU1PSExmcVZwYzlqRGFxVEV1N1ZSMXV6c0Q3Rjl5XzBoZnFlaUVqY1dyOEk3ZkV0TjEwN2FkUmpPbnJ3LXZ3OVpWaEpRTFFxU1pKRE81SDlva1lmNEdoY05fNVA0eU9jSnB2N0FXR3RYT0UxdVVHMGprbGQ2YTdrbHdHTC1aTEE?oc=5","date":"2025-09-28","type":"pipeline","source":"MedicalResearch.com","summary":"Hip and Knee Replacements More Common In Patients With Transthryretin Cardiac Amyloidosis - MedicalResearch.com","headline":"Hip and Knee Replacements More Common In Patients With Transthryretin Cardiac Amyloidosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5xZmVidDdVaFM2c3lUUG43M3V5cGo5aVVDbDVaX1FBWENPTTNmZV9LamJ4aC1hWnluZkZaOGpkWnVTcXlLWlMxVzlyZnl1b04xM2pJUDAyU1FoeC0zU1dSbW4xNXFIX0RMdE8yaDA1SHphcXRrdHUzVzNnQQ?oc=5","date":"2025-02-18","type":"pipeline","source":"American Heart Association Journals","summary":"Guideline-Directed Medical Therapy for Heart Failure in Transthyretin Amyloid Cardiomyopathy - American Heart Association Journals","headline":"Guideline-Directed Medical Therapy for Heart Failure in Transthyretin Amyloid Cardiomyopathy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBQeXA5VkM1X1ZyOGhtS0l3TmJnRW5aYnFrcWVib3M4aExzeGJ3dlJQbU5uT2R5T1lsWEtaMHlKU0tvOVllVGtDdzFMTmF4TlJ5aHd1eVFYZC0wU2tPcGxtTg?oc=5","date":"2025-01-22","type":"trial","source":"JACC Journals","summary":"Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial - JACC Journals","headline":"Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE9ONGRnWmhrU21yYjAyY0RyVTVKT2tJT21uMG81d0RfMU9leXM4OHVxc1Vfb0Q1UF9MRmNWMEV5THdyS0R0SFFKVTBUajlSTHlvRUZyQ0stMmVQV3NHSmZCakpvQ1dGdTNydk5LbnUwVVhVSjlaUUNlaA?oc=5","date":"2024-11-18","type":"regulatory","source":"American Heart Association Journals","summary":"Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial | Circulation - American Heart Association Journals","headline":"Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPcjFwMHZLbjUzMTRkc3pkSHI1ZERWSGtqcG1ucmxBZTd4UUdRZkpBSXBHV0M0Y00tLVd5a2NYYm9OZlZZUm9EX0lPRHF1c01jVGJjX2lWSXhXWHBUVnpQeDdPeWVIX21EcWVVdkRDZFpsSGhQVlNpTzZGRDhPR2hrZEw5V05UclI3ejhISTZ4NA?oc=5","date":"2024-10-04","type":"trial","source":"TCTMD.com","summary":"Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM - TCTMD.com","headline":"Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNTjhZTUdOV3FaemhwUlQyWEp4WWc4X3N3ZjhKUmRTdjltakRDTjJmcG4ycV9LUTdIb01KTE1xREhmSGE5eGdCQ3dxczhRUTlFWkRvYWJRR1dpZUsxYmlBamo1TkdHS1I1OG5ZbDZKNF9ZT1RRcFFYV3dDWXRycUhpc1FQZHNHa2VCdFpSSUFEaFNQMVJxYV9UeDZhTENTSFZxNmZvNkFwVWVwME12YUNRTHFPUjhxb21GZjJyaDdVeHI1Rk9KVlY0SmhjTy0?oc=5","date":"2024-03-29","type":"pipeline","source":"American College of Cardiology","summary":"Feature | Cardiac Amyloidosis and How to Stop Missing the Diagnosis - American College of Cardiology","headline":"Feature | Cardiac Amyloidosis and How to Stop Missing the Diagnosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE43bGR2T1d1SDFxaGZpOC1QTEhZc0h2RHV1TWowUWJESGJwa3lFV2lfU1RVcWtFdGpRSzlHSEU2ZjdBaWxiN3M2T1FhUG0zc2ppQTY0UDdrb2JNVGRXeFJZ?oc=5","date":"2023-11-27","type":"pipeline","source":"Nature","summary":"Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis | Blood Cancer Journal - Nature","headline":"Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis | Blood Cancer Journal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE5NaXFFMHc1amNTNlhUeGQwLVloa2cyUWcwcU9JeXRWblA2WC1DQy1KZFlET0lGcHBNb2xHV2hUV1JzLU1FellvTnpZRENPSUtkdFVaT1FROUZsX0RfbVFyQg?oc=5","date":"2023-10-25","type":"pipeline","source":"NEJM","summary":"Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis - NEJM","headline":"Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE9Ec2U1VTdRTG9FdHYtbElaTVU3ZHhKQjctQUN0dGhReUhERm5FTWp1QUdyX2h6TVZxbDRnanVnMGVaZkI1d2JtTktBQTc3STQ3b29MS2c5TFNuaV9aaTNwN2NCVDlZZw?oc=5","date":"2023-04-17","type":"trial","source":"American Heart Association Journals","summary":"Design and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study - American Heart Association Journals","headline":"Design and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOYzJlQmJWb2FaLXA0c3h2Wk5OdERYTTV0RjBFRHJfTDNNV2JkMGNjWFd1dVRSX1lPRDBiR05GZFFqVnhPbGhfbmlhcWhmU2hfZXF2SVBBNEpnQWpEVFhfZTJFU1d2OU85czU3bGNsOVM0WlJ5RXFoT2NFS2x2VXBPWWZxSExhSkJNamNYU0haQXlDYkxiX3lsYTBJejd0cGxqdXdzRF9JT0FrX2NpaXhHX3VyOG0tazlPM0Rn?oc=5","date":"2020-06-19","type":"trial","source":"Fierce Pharma","summary":"Pfizer's blockbuster-to-be Vyndaqel is too costly for heart patients, study suggests - Fierce Pharma","headline":"Pfizer's blockbuster-to-be Vyndaqel is too costly for heart patients, study suggests","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE4zQXhLaWdYY0FvYTJwZWFhajJBX2NJQzlYOUYyaHNUd1JBYVNtTlJCelNGbTllelQ1a0NsOGhWWHNBUVh3Y0RkYi1CaXcyTkc0MlB3a205TXFpWFVNX0NxXw?oc=5","date":"2018-08-27","type":"pipeline","source":"NEJM","summary":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy - NEJM","headline":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}